CEL-SCI TO PRESENT AT 2018 BIO CEO & INVESTOR CONFERENCE

Vienna, VA, February 5, 2018 -- CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.

A live audio webcast of the presentation and replay will be available under the investor relations section of CEL-SCI's website at www.cel-sci.com/investor_relations.html. The replay of the presentation will be available approximately 1 hour after the presentation and is accessible until May 14, 2018.

Hosted by the Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference will take place February 12-13 at the Marriott Marquis in New York City. Now in its 20th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

About CEL-SCI Corporation

CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma.

The Company's LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.